Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 1,057 Shares

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 1,057 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $10.02, for a total transaction of $10,591.14. Following the completion of the sale, the president now owns 2,915,194 shares in the company, valued at $29,210,243.88. The trade was a 0.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total transaction of $565.60.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total value of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total value of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.50, for a total value of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.27, for a total transaction of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.82, for a total transaction of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Up 5.3 %

Gyre Therapeutics stock opened at $10.52 on Wednesday. The company has a 50 day moving average price of $11.83 and a 200 day moving average price of $12.66. Gyre Therapeutics, Inc. has a 52 week low of $8.26 and a 52 week high of $26.37.

Institutional Trading of Gyre Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC acquired a new position in Gyre Therapeutics during the third quarter valued at $47,000. Barclays PLC grew its stake in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics in the 2nd quarter valued at about $123,000. Renaissance Technologies LLC purchased a new stake in shares of Gyre Therapeutics in the second quarter worth approximately $166,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Gyre Therapeutics in the second quarter worth approximately $218,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.